Trade Desk Inc vs Viatris Inc — how do they compare? Trade Desk Inc trades at $12.38 (market cap $5.83B), while Viatris Inc trades at $17.47 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 3.4× Trade Desk Inc's market cap, and Viatris Inc pays a 2.75% dividend while Trade Desk Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Trade Desk Inc for 72 Days and Viatris Inc for 57 Days on average.
| TTD | VTRS | |
|---|---|---|
Market Cap | $5.83B | $20.03B |
Volume | 15,864,392 | 14,109,977 |
Sector | Media | Health |
52-Week High | $54.13 | $18.27 |
52-Week Low | $11.92 | $9.74 |
Typical Hold Time | 72 Days | 57 Days |
Enterprise Value | $4.78B | $32.15B |
Dividend Yield | — | 2.75% |
Signals from Pluang's Aura AI — not financial advice
TTD trades at $12.09, up 1.43% on the day but remains under pressure with a bearish technical signal. Revenue grew to $2.90B in 2025, though net income margin slipped to 15.3%. Recent earnings show volatility, with a Q2 beat but Q1 miss. The stock faces stiff competition and slowing growth, reflected in negative cash flow trends and a workforce reduction announced in September 2026.
The outlook is cautious; while valuation ratios appear low, competitive threats from tech giants and declining growth pose significant risks. Analyst consensus is mixed with a $14.72 price target, but the stock's 68% YTD drop underscores investor skepticism. Upside depends on execution in connected TV and new verticals like healthcare ads.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.
The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →